Response to R115777 in MDS patients
Patient . | Diagnosis . | Response . | Duration, mo . | Total daily dose, mg . | ras Mutation . |
|---|---|---|---|---|---|
| 2 | RAEB | HI | 16 | 300* | No |
| 3 | CMMoL | HI | 2 | 600 | Yes (k-ras) |
| 6 | CMMoL | PR | 6 | 600 | Yes (n-ras) |
| 12 | CMMoL | PR | 16+ | 800 | No |
| 16 | RAEB | HI | 3 | 900 | No |
| 21 | RAEB-T | CR | 9+ | 800 | No |
Patient . | Diagnosis . | Response . | Duration, mo . | Total daily dose, mg . | ras Mutation . |
|---|---|---|---|---|---|
| 2 | RAEB | HI | 16 | 300* | No |
| 3 | CMMoL | HI | 2 | 600 | Yes (k-ras) |
| 6 | CMMoL | PR | 6 | 600 | Yes (n-ras) |
| 12 | CMMoL | PR | 16+ | 800 | No |
| 16 | RAEB | HI | 3 | 900 | No |
| 21 | RAEB-T | CR | 9+ | 800 | No |
Time of initiation of the protocol predated the publication of the international response criteria.34 However, reanalysis of the data according to those criteria does not change the response designation.
Patient started at a total daily dose of 600 mg/d, but dose was reduced after 2 weeks.